Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.710
+0.080 (4.91%)
At close: Oct 29, 2024, 4:00 PM
1.700
-0.010 (-0.58%)
After-hours: Oct 29, 2024, 7:56 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 5.75, with a low estimate of 4.00 and a high estimate of 7.50. The average target predicts an increase of 236.26% from the current stock price of 1.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AKBA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +338.60% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +338.60% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +338.60% | Oct 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +338.60% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $7.5 | Strong Buy | Maintains | $6 → $7.5 | +338.60% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
175.44M
from 194.62M
Decreased by -9.86%
Revenue Next Year
181.10M
from 175.44M
Increased by 3.23%
EPS This Year
-0.25
from -0.28
EPS Next Year
-0.26
from -0.25
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 186.4M | 244.1M | 261.2M | ||
| Avg | 175.4M | 181.1M | 251.4M | ||
| Low | 158.7M | 126.7M | 239.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.2% | 39.2% | 44.2% | ||
| Avg | -9.9% | 3.2% | 38.8% | ||
| Low | -18.5% | -27.8% | 32.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.17 | 0.09 | 0.44 | ||
| Avg | -0.25 | -0.26 | 0.15 | ||
| Low | -0.32 | -0.46 | -0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.